Mobilization of peripheral blood progenitor cells for allogeneic transplantation.
Allogeneic transplantation of peripheral blood stem/progenitor cells (PBSC/PBPC) has been increasingly used as an alternative to allogeneic bone marrow transplantation. To mobilize and collect a sufficient number of PBSC/PBPC for engraftment after allotransplantation, granulocyte colony-stimulating factor (G-CSF) has been preferentially used. The mobilization protocol, however, has not been fully established. In this review, dose and schedule of G-CSF administration, characteristics of G-CSF-mobilized PBPC products, cytokines other than G-CSF for PBSC/PBPC mobilization, and safety of the PBSC/PBPC donors are discussed for clinical application of allogeneic PBSC/PBPC transplantation.
Teshima
A
A
Department of Medicine II, Okayama University Medical School, Japan.
Harada
M
M
D018952:Antigens, CD34 / Q000378:metabolism; D001782:Blood Donors; D002452:Cell Count; D016207:Cytokines / Q000008:administration & dosage / Q000009:adverse effects; D004992:Ethics, Medical; D006085:Graft Survival; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000639:trends; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007700:Kinetics; D007937:Leukapheresis / Q000009:adverse effects; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D009000:Monocytes / Q000166:cytology / Q000187:drug effects; D012449:Safety; D013921:Thrombocytopenia / Q000209:etiology; D014184:Transplantation, Homologous
D018952:Antigens, CD34; D016207:Cytokines; D016179:Granulocyte Colony-Stimulating Factor